Table 5. Basophilic leukemias (BL) described in the literaturea .
| Case # | Underlying primary diagnosisb | Type of BL | Age (yrs) | Sex (m/f) | Karyotype | WBC G/L | % BA in PB | % Blasts in PB | % BA in BM | % Blasts in BM | Primary therapy | Remission status | Survival (months) | Reference #a,c |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | CML-BP | ABL | 37 | f | 46XX, t(9;22) | 57.8 | 49 | 45 | 20.6 | 66 | Poly-CT | NR | 16 | S1 |
| #2 | n.r. | BL | 59 | f | n.r. | 70 | 82 | n.r. | 28 | n.r. | n.r. | n.r. | 3 | S2 |
| #3 | n.r. | BL | 39 | m | 48XY, complex | 27.2 | 77 | n.r. | 27.8 | n.r. | n.r. | n.r. | 2.5 | S3 |
| #4 | CML-AP | BL | 31 | m | 48XY, complex +8,+19, t(9;22) | 34 | 78 | n.r. | 57 | n.r. | n.r. | n.r. | 3 | S4 |
| #5 | n.r. | BL | 46 | m | n.r. | 13.6 | 78 | n.r. | 37 | n.r. | n.r. | n.r. | 3 | S5 |
| #6 | n.r. | BL | 27 | m | 51XY, complex | 17.7 | 45 | n.r. | n.r. | n.r. | n.r. | n.r. | 2.5 | S6 |
| #7 | n.r. | BL | 55 | m | n.r. | 24.3 | 52 | n.r. | 4.2 | n.r. | n.r. | n.r. | 2 | S7 |
| #8 | CML-AP | BL | 77 | f | 46XX, complex with t(9;22) | 93 | 40 | n.r. | 33.2 | n.r. | n.r. | n.r. | 5 | S8 |
| #9 | CML-AP | BL | 50 | f | 47XX, complex with t(9;22) | 47.9 | 47 | n.r. | 29 | n.r. | n.r. | n.r. | 1.5 | S9 |
| #10 | n.r. | BL | 43 | m | n.r. | 20.5 | 94 | n.r. | n.r. | n.r. | n.r. | n.r. | 6 | S10 |
| #11 | CML-BP | ABL | 26 | f | Complex with t(9;22) | 35 | 57 | n.r. | 26 | 33 | Poly-CT | n.r. | 4 | S11 |
| #12 | AML | ABL | 7 | m | 46XY, t(8;21) | 75 | 2 | 54 | 40 | 3 | Poly-CT | NR | 2 | S12 |
| #13 | n.r. | CBL | 68 | f | 47, XX, der(6) | 57.9 | 84 | 0 | 75 | <5 | HU | CR | >36 | S13 |
| #14 | CML-BP | ABL | 44 | f | 47, XX, +19 t(9;22), | 23 | 40 | 0 | 80 | 20 | n.r. | n.r. | n.r. | S14 |
| #15 | MDS | CBL | 84 | f | Complex | 34.2 | 44 | 0 | n.r. | n.r. | HU | n.r. | >3 | S15 |
| #16 | CML-BP | ABL | 30 | m | Complex with t(9;22) | 109.7 | 90 | >20 | n.r. | n.r. | n.r. | n.r. | n.r. | S16 |
Abbreviations: BM, bone marrow; CR, complete remission; f, female; HU, hydroxyurea; m, male; MDS, myelodysplastic syndrome; n.r., not reported; NR, no remission; PB, peripheral blood; poly-CT, polychemotherapy; WBC, white blood count; yrs, years.
Only cases that were described/classified as basophilic leukemia by the reporting authors and were presented with a percentage count of at least 40% basophils (BA) were selected (of ≈50 cases screened). BA included mature and immature basophilic cells as well as metachromatic (basophilic) blasts.
The underlying diagnoses were either reported by the authors or were ‘established’ based on information provided in the literature and the currently available WHO criteria. Regarding basophilic leukemia, patients were classified as ABL or CBL based on the percentage of blasts (<20% =CBL; ⩾20%= ABL). Cases without a reported blast count were classified as basophilic leukemia (BL).
References are included in the Supplementary Material.